Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
Issell
B F
BF
Einhorn
L H
LH
Comis
R L
RL
Lawson
R D
RD
Baker
L H
LH
Harvey
H A
HA
Lanzotti
V A
VA
Wampler
G L
GL
Daniels
J R
JR
Anderson
P N
PN
D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D009096:Multi-Institutional Systems; D009325:Nausea / Q000139:chemically induced; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D014839:Vomiting / Q000139:chemically induced
D005047:Etoposide; D011034:Podophyllotoxin